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 28 
Abstract 29 
Preeclampsia (PE) is a hypertensive disorder of pregnancy that is a major cause of maternal-fetal 30 
morbidity and mortality worldwide. Severe PE (sPE) is mediated by pathology of the placental 31 
villi resulting in repressed PlGF production and hyper-secretion of sFLT1, the net effect being 32 
widespread maternal endothelial dysfunction. Villous trophoblast differentiation is under control 33 
of the PPARγ and GCM1 axis which is dysregulated in sPE. We hypothesized that disruption of 34 
trophoblast differentiation via the PPARγ-GCM1 axis is a major contribution to excess production 35 
of sFLT1 and pharmacological activation of PPARγ in the sPE placenta could reduce sFLT1 to 36 
normal levels. sPE, age-matched control placentas and first trimester villous explants were used to 37 
investigate the molecular relationships between PPARγ-GCM1 and sFLT1. We modulated this 38 
pathway by pharmacologic activation/inhibition of PPARγ using Rosiglitazone and T0070907, 39 
respectively and through siRNA repression of GCM1. PPARγ and GCM1 protein expressions are 40 
reduced in the sPE placenta while FLT1 protein and sFLT1 secretion are increased. GCM1 41 
reduction in the first trimester explants significantly increased sFLT1 secretion, suggesting GCM1 42 
as a key player in this pathway. Activation of PPARγ restored GCM1 and significantly reduced 43 
sFLT1 expression and release in first trimester and sPE placental villi. Functional integrity of the 44 
PPARγ-GCM1 axis in the villous trophoblast is critical for normal pregnancy development and is 45 
disrupted in the sPE placenta to favor excessive production of sFLT1. Pharmacologic manipulation 46 
   
 
   
 
of PPARγ activity has the potential to rescue the anti-angiogenic state of sPE and thereby prolong 47 
pregnancy and deliver improved clinical outcomes. 48 
Keywords: PPARγ; GCM1; Human placenta; FLT1; Preeclampsia; Pregnancy 49 
 50 
Introduction 51 
The placenta serves as a critical organ during pregnancy to support fetal growth and 52 
development [1-3]. Abnormal placental development is a hallmark of several pregnancy-related 53 
complications causing significant maternal and/or fetal morbidity and mortality, especially severe 54 
fetal forms of fetal growth restriction (sFGR) and preeclampsia (sPE) that result in stillbirth or 55 
early preterm delivery [3, 4]. sPE comprises new onset of maternal hypertension after 20 weeks of 56 
gestation with systemic endothelial dysfunction and critical end-organ injury involving the 57 
kidneys, liver, brain and coagulation system [1, 5]. In sPE, the placenta most commonly exhibits 58 
multiple histopathologic features, collectively described as maternal vascular malperfusion [4, 6]. 59 
The disease begins with reduced extravillous trophoblast invasion and transformation of the 60 
uteroplacental arteries, which results in chronic ischemia of the developing placental villi [6-8]. 61 
Patients at highest risk of sPE demonstrated bilateral abnormal uterine artery Doppler and low 62 
circulating levels of placenta growth factor (PIGF) [9] and subsequently begin to express very high 63 
levels of soluble fms-like tyrosine kinase 1 (sFLT1) [10, 11]. In combination, the high sFLT1/PlGF 64 
ratio is now an established diagnostic test for PE [12, 13].  65 
 sFLT1 is a potent anti-angiogenic protein and major contributor to endothelial damage in 66 
PE [14]. sFLT1 is a splice variant of the vascular endothelial growth factor receptor 1 (VEGFR1) 67 
also known as FLT1. sFLT1 competitively binds to the receptor domains of vascular endothelial 68 
growth factor (VEGF) [15] and its dimeric partner PIGF [16], preventing their interaction with the 69 
   
 
   
 
endothelial cell surface receptors. Our group previously found that first trimester placentas secrete 70 
higher amounts of sFLT1 by tissue weight compared to healthy term placenta, suggesting that 71 
sFLT1 has important roles in early pregnancy [17]. Increased levels of sFLT1 throughout 72 
pregnancy combined with lowered levels of PlGF largely mediates the systemic endothelial 73 
dysfunction observed in PE [18-21].  74 
The transcription factor, Glial cell missing 1 (GCM1) regulates villous trophoblast 75 
differentiation in human placental villi [22, 23] and analogous labyrinth formation in mice [24, 76 
25]. GCM1 thereby modulates the expression of trophoblast-derived proteins involved in the 77 
maintenance of normal pregnancy and cardiovascular function, especially the promotion of PIGF 78 
following syncytial fusion [16]. Prior reports found reduced GCM1 expression in PE placentas 79 
[26] with similar repression of the downstream fusogenic partner, syncytin, that is required for 80 
syncytiotrophoblast fusion to grow the continuous outer layer covering the placental villi. GCM1 81 
is a strong candidate to regulate sFLT1 production in human placental villi, since a previous study 82 
identified that heterozygous Gcm1 knockout murine placentas secrete significantly higher levels 83 
of sFLT1 [27]. In further support of this hypothesis, enhanced expression of GCM1 via anti-viral 84 
drugs reduced the expression of sFLT1 in murine placentas [28].  85 
GCM1 and the nuclear steroid receptor, peroxisome proliferator activated receptor gamma 86 
(PPARγ), are critical proteins needed for placental development and pregnancy. PPARγ and 87 
GCM1 work as sequential partners to regulate proper villous trophoblast to syncytiotrophoblast 88 
differentiation [23, 27]. PPARγ functions as an upstream transcriptional regulator of GCM1 [25, 89 
29] through binding at two PPARγ response elements in the GCM1 promoter [30]. Using the 90 
BeWo choriocarcinoma villous trophoblast cell line [30] and a first trimester placenta explant 91 
model [22], our group previously identified that pharmacological activation of PPARγ by 92 
   
 
   
 
Rosiglitazone led to an increase in GCM1 expression and villous trophoblast differentiation. These 93 
findings suggest that this pathway is important for normal trophoblast function and turnover.  94 
In the past decade, PPARγ has emerged as an important player in placental development 95 
due to its regulatory roles in multiple cellular pathways including metabolism, nutrient balance, 96 
and anti-inflammatory response pathways [31-33]. Murine studies have shown that embryonic 97 
knockdown of PPARγ is lethal due to gross cardiovascular and placental abnormalities [34]. Prior 98 
studies have shown that hypoxia reduces PPARγ expression in the human placenta and murine 99 
trophoblast stem cells [35-37]. Therefore, the prolonged hypoxic/ischemic nature of the severe PE 100 
placenta is likely a cause for the reduced placenta expression of PPARγ observed in PE [38-41]. 101 
This further imposes an abnormal villous trophoblast structure and poorly-developed feto-102 
placental vasculature observed in severely preeclamptic placentas [34]. In a rodent model of PE, 103 
decreased activity of PPARγ was found to correlate with increased sFLT1 levels [42] and re-104 
introducing PPARγ in PPARγ-/- murine trophoblast stem cells rescued differentiation of the 105 
syncytiotrophoblast and labyrinthine trophoblast lineages by GCM1 upregulation [25].  106 
While it is established that PPARγ and GCM1 are critical factors for normal placental 107 
development, the potential molecular connections between PPARγ, GCM1, and sFLT1 in the 108 
normal and diseased human placenta are unclear. In the current study, we hypothesized that 109 
maintenance of the PPARγ-GCM1 axis in healthy developing placental villi represses the 110 
expression and secretion of the anti-angiogenic sFLT1, whereas this axis is disrupted in favor of 111 
hyper-secretion of sFLT1. We tested this hypothesis in explanted human placental villi from first 112 
trimester or from healthy and severely-preeclamptic women to determine the expression of GCM1 113 
and production of sFLT1, under conditions that pharmacologically activated or inhibited PPARγ 114 
via the drugs Rosiglitazone and T0070907, respectively.   115 
   
 
   
 
Results 116 
Cultured sPE placentas show increased protein expression of FLT1, increased secretion of 117 
sFLT1 and reduced protein expression of PPARγ and GCM1 compared to PTC controls. 118 
sFLT1 secretion into the placenta culture media was measured by ELISA after 48 hours of culture 119 
for sPE and gestational age-matched preterm control (PTC) placentas. We observed significantly 120 
higher secretion of sFLT1 from sPE placentas compared to PTC (3327±198 pg/mL vs. 2361±198 121 
pg/mL, p=0.0067, n=5, Fig. 1A). Placental protein expression of FLT1, PPARγ, and GCM1 were 122 
measured by western blotting. FLT1 protein expression was significantly upregulated in sPE 123 
placentas comparison to PTC (0.96±0.2 vs. 0.28±0.06 relative expression values, p=0.0167, n=6, 124 
Fig. 1B) which mirrored representative immunohistochemical staining patterns showing enhanced 125 
localized expression of total-FLT1 (which includes all FLT1 and sFLT1 variants) in the 126 
syncytiotrophoblast layer of the sPE placenta (Figure 1E). sPE placentas showed a significant 127 
reduction of PPARγ protein expression (0.476±0.13 vs. 1.09±0.1, p=0.0042, n=6, Fig. 1C, F) and 128 
a significant reduction of GCM1 protein expression (0.56±0.06 vs. 0.99±0.07, p=0.0001, n=14, 129 
Fig. 1D, F) compared to PTC.  130 
Activation of PPARγ by Rosiglitazone induces GCM1 expression and lowers placental 131 
sFLT1 secretion in first trimester placental explants. First trimester villous placental explants 132 
were used as a model to understand how sFLT1 changes in response to modulating of the PPARγ–133 
GCM1 axis. These tissues were cultured for 18 hours with PPARγ agonist, Rosiglitazone (10mM), 134 
or antagonist, T0070907 (1mM). Successful activation of PPARγ by Rosiglitazone was confirmed 135 
by a 28±5% increase in PPARγ global DNA-binding activity in the Rosiglitazone treated explants 136 
(128±5 vs. 100, p<0.05, n=3, Fig. 2A) as measured by an ELISA-based transcription factor binding 137 
assay. There was no significance difference in PPARγ DNA-binding activity in the T0070907 138 
   
 
   
 
treated explants (Fig. 2A). PPARγ and GCM1 protein expressions in first trimester tissues were 139 
measured by western blotting. Rosiglitazone significantly increased PPARγ protein expression 140 
(1.3±0.09 vs 1, p=0.0446, n=4, Fig. 2B, F) and GCM1 protein expression (1.83±0.2 vs. 1, 141 
p=0.0402, n=4, Fig. 2C, F). Rosiglitazone significantly increased GCM1 mRNA expression 142 
(2.35±0.4 vs. 1, p=0.04, n=4) while T0070907 significantly decreased GCM1 mRNA expression 143 
(0.55±0.1 vs. 1, p=0.02, n=4) (Fig. 2D). Rosiglitazone significantly decreased sFLT1 secretion 144 
into the culture media (0.57±0.07 vs. 1, p=0.025, n=3, Fig. 2E). Treatment with T0070907 did not 145 
result in a significant change in sFLT1 secretion from the first trimester explants (Fig. 2E).   146 
Silencing of GCM1 upregulates FLT1 and sFLT1 in human first trimester explants.  147 
We have shown that activating PPARγ in the placenta leads to a significant induction of GCM1 148 
mRNA and protein expression and a significant reduction of sFLT1 secretion from the first 149 
trimester placenta. Since it is already established that PPARγ acts as an upstream transcriptional 150 
regulator for GCM1 [30], we aimed to determine if GCM1 has a role in this potential pathway for 151 
regulation of sFLT1 secretion. We further used first trimester villous explants as a model for 152 
siRNA-mediated repression of GCM1. GCM1 siRNA caused a significant reduction of GCM1 153 
mRNA expression (0.49±0.09, p=0.031, n=3, Fig. 3A) and reduced GCM1 protein as compared to 154 
tissues transfected with the scramble siRNA (Fig. 3C). The GCM1-silenced explants secreted 155 
significantly more sFLT1 (1.59±0.13 vs. 1, p=0.0389, n=3, Fig. 3B). A representative 156 
immunohistochemistry staining shows higher expression of total-FLT1 protein (FLT1 and sFLT1 157 
variants) in the syncytiotrophoblast of the GCM1-silenced explants compared to scramble siRNA 158 
and no-treatment controls (Fig. 3D).  159 
Rosiglitazone restores PPARγ and GCM1 expression and downregulates sFLT1 in the severe 160 
preeclamptic placenta.  To test if the PPARγ-GCM1 axis can be modulated in the sPE placenta, 161 
   
 
   
 
we pre-treated sPE placentas with Rosiglitazone (10µM) or T0070809 (1µM) for 24 hours. 162 
Rosiglitazone significantly increased PPARγ protein expression in sPE (1.34±0.04 vs. 1, p=0.051, 163 
n=4) and treatment with T0070907 did not have a significant effect on PPARγ protein expression. 164 
Rosiglitazone restored GCM1 by increasing mRNA expression the sPE placenta (1.28±0.09 vs. 1, 165 
p=0.0162, n=9, Fig 4A). Treatment with T0070907 caused a significant reduction of GCM1 166 
mRNA expression in the sPE placenta (0.49±0.05 vs. 1, p=0.001, n=9, Fig. 4A). Rosiglitazone 167 
significantly decreased sFLT1 mRNA expression in the sPE placenta (0.655±0 vs. 1, p=0.0058, 168 
n=7, Fig 4B). Treatment with T0070907 did not cause a significant change in sFLT1 mRNA 169 
expression in the sPE placenta (Fig. 4B). 170 
 171 
Discussion  172 
 In this study, we provide novel molecular evidence to demonstrate that FLT1 and its 173 
secreted splice variant, sFLT1, are regulated by a PPARγ–GCM1 axis in the trophoblast layer 174 
covering human placental villi. Under physiologic conditions, this axis mediates orderly 175 
syncytiotrophoblast formation via asymmetric divisions of progenitor villous cytotrophoblasts 176 
[43], which in turn promotes PlGF synthesis and release into maternal blood, and in tandem, 177 
represses sFLT1 [16, 22, 23, 27]. Conversely, under sub-optimal PPARγ–GCM1 signaling, the 178 
placental villi show both structural and molecular defects characterized by defective syncytial 179 
fusion, repressed PlGF and aberrant release of sFLT1 into maternal blood [26, 38-41]. sFLT1 plays 180 
a major role in PE pathology as it promotes wide-spread endothelial dysfunction which largely 181 
contributes to the multi-organ dysfunction in the mother [7, 44, 45]. Highly secreted sFLT1 and 182 
its anti-angiogenic properties are well characterized in sPE placentas, where syncytial knot 183 
   
 
   
 
formation is one of the hallmarks of the maternal-vascular malformation disease [46, 47]. While 184 
FLT1 is known to be increased in tissues during vascular reoxygenation in response to 185 
hypoxic/ischemic insult [48] which similarly occurs in the PE placenta [49], the regulatory 186 
mechanism(s) of FLT1 and sFLT1 in the placenta remains unclear.  187 
We observed higher sFLT1 secretion and higher protein expression of FLT1 in the PE 188 
placenta. Additionally, our immunohistochemistry staining identified that total-FLT1 protein 189 
(FLT1 and sFLT1 variants) exclusively localized to the syncytiotrophoblast in both control and 190 
sPE placenta, and appears to have increased localization in the syncytial knots found in sPE tissue. 191 
Our data validates previous findings by Taché et al., who showed a correlation between high 192 
syncytiotrophoblast sFLT1 levels and PE disease severity [46]. In addition, Jebbink et al. showed 193 
syncytiotrophoblast specific localization of sFLT1 mRNA transcripts and higher sFLT1 mRNA in 194 
the PE placenta [20]. Together, these data support the notion that the abnormal syncytiotrophoblast 195 
layer in PE may be the major source of high secretion of sFLT1. 196 
Our data shows an inverse correlation between high FLT1 expression and sFLT1 secretion 197 
and low PPARγ and GCM1 expression in the PE placenta. This finding aligns with previous reports 198 
in the literature [23, 26, 27]. The relationship between PPARγ and sFLT1/FLT1 in the placenta 199 
was previously shown in a study by McCarthy et al., where a reduced utero-placental perfusion 200 
pressure (RUPP) model was established to mimic PE in pregnant rats [50]. These RUPP animals 201 
showed significantly elevated levels of sFLT1 [50]. When treated with Rosiglitazone, these 202 
animals showed decreased blood pressure and decreased levels of sFLT1 [50]. In a separate study, 203 
McCarthy et al. treated pregnant rats with the PPARγ antagonist, T0070907, which caused these 204 
animals to develop PE-like symptoms such as elevated blood pressure and proteinuria 205 
accompanied by decreased VEGF and increased plasma levels of sFLT1 [42].  206 
   
 
   
 
From this finding and our observations that PPARγ and GCM1 are inversely correlated 207 
with FLT1 expression, we hypothesized that a molecular connection exists between PPARγ, 208 
GCM1, and FLT1/sFLT1 in the human placenta, via repression of syncytin-mediated syncytial 209 
fusion. We used our first trimester placental explant model to test if this pathway can be modulated 210 
in the placenta. We used the PPARγ agonist, Rosiglitazone, and PPARγ antagonist, T0070907, to 211 
modulate this pathway. T0070907 antagonizes PPARγ by selectively binding to the PPARγ ligand 212 
binding pocket, preventing its activation by another ligand [51]. It is suggested that repressive 213 
ligands such as T0070907 do not have an effect on PPARγ protein expression levels [51], which 214 
could explain our finding that PPARγ protein expression was not significantly different in first 215 
trimester placenta or in sePE placentas when treated with T0070907. Rosiglitazone acts as a 216 
chemical ligand for PPARγ by increasing its DNA-binding activity to influence gene expression 217 
[32] and is also shown to increase PPARγ transcription [52]. We confirmed that Rosiglitazone 218 
caused an increased in PPARγ activity in the first trimester explants and this coincided with a 219 
significant increase in PPARγ protein expression in the first trimester explants and in the sePE 220 
placenta. We observed that Rosiglitazone significantly upregulated GCM1 mRNA and 221 
significantly reduced sFLT1 secretion into placental media culture in our first trimester explant 222 
model. These results suggest that the PPARγ-GCM1 axis has a role in regulating the angiogenic 223 
environment of the placenta via sFLT1. 224 
 We further questioned whether the changes observed in sFLT1 secretion were a direct 225 
result from PPARγ activation or if GCM1 may serve as an intermediate in this pathway to modulate 226 
FLT1 expression, since PPARγ transcriptionally regulates GCM1 through two PPARγ response 227 
elements in the promoter region of GCM1 [30]. We show that siRNA mediated repression of 228 
GCM1 in our first trimester villous explants caused a significant upregulation of sFLT1 secretion, 229 
   
 
   
 
as well, caused an increase in FLT1 protein expression in the syncytiotrophoblast, observed 230 
through immunohistochemistry. Our findings align with previous studies that showed a 231 
heterozygous knockdown of Gcm1 in the mouse led to increased secretion of sFLT1 [27]. These 232 
results suggest that GCM1 may be involved in FLT1 regulation and a decrease of GCM1 233 
expression may contribute to the anti-angiogenic state during PE through upregulation of sFLT1. 234 
We lastly show that this pathway is not unique to the first trimester placenta and can be modulated 235 
in the diseased severely preeclamptic placenta. We found that activation of PPARγ in sPE placenta 236 
increased GCM1 and reduced sFLT1 mRNA expression.  237 
In the current study, we show for the first time that activation of PPARγ can modulate the 238 
angiogenic environment of the human placenta by altering expression of GCM1, FLT1 and sFLT1. 239 
More studies are needed for better understanding of how this pathway impacts placental function 240 
and physiology during the second and third trimesters of pregnancy, when the high anti-angiogenic 241 
environment in PE becomes largely problematic. We acknowledge the limitations of our study, 242 
such as small sample size which necessitates follow up studies with larger cohorts. We were unable 243 
to observe an effect based on mode of delivery however this should be considered as a confounding 244 
factor in future studies. To our knowledge, we report novel findings of PPARγ, GCM1 and sFLT1 245 
in the placenta, although we have not clearly demonstrated that a direct or indirect interaction 246 
between these molecules exist. We performed in silico prediction of DNA-binding sites for GCM1 247 
in the promoter region FLT1 using data from HOmo sapiens COmprehensive MOdel COllection 248 
(HOCOMOCO) v9 [53]. No putative binding site for GCM1 was found in the proximity of the 249 
FLT1 active promoter however there are two putative GCM1 binding sites approximately ~50kb 250 
from the FLT1 promoter (Supplemental Figure 3). Further studies should focus on potential long-251 
range effects of GCM1 at these regions to regulate FLT1 promoter elements, co-factors or splicing 252 
   
 
   
 
machinery to directly influence gene expression or protein secretion of FLT1 and its splice 253 
variants. Moreover, future studies should consider how modulating this pathway could affect 254 
overall angiogenic balance, such as through increasing secretion of PIGF and VEGF from the 255 
placenta. Detailed molecular studies investigating these targets potentially using both in vivo and 256 
in vitro models with knockdown or knockout of PPARγ and GCM1 are needed to fully understand 257 
this potential mechanism and their effects on overall placental function. 258 
 259 
Perspectives 260 
Abnormal trophoblast differentiation and turnover poses a major threat to placental function in 261 
preeclampsia (PE) and is driven by dysregulation of the PPARγ-GCM1 syncytialization axis. We 262 
identify that high FLT1 expression localizes to the damaged syncytial membrane in the 263 
preeclamptic placenta. Silencing of GCM1 in the human placenta significantly upregulates sFLT1 264 
secretion and causes intense FLT1 localization to the GCM1-deficient syncytiotrophoblast, further 265 
suggesting that dysregulation of villous trophoblast turnover is responsible for the high FLT1 and 266 
pathologic levels sFLT1 observed in PE. Our data position PPARγ proximal to GCM1 to regulate 267 
its expression, as we show that induction of PPARγ restores GCM1 while providing a physiologic 268 
brake on sFLT1 production, and further affords the PPARγ-GCM1 axis a therapeutic target status. 269 
Our study highlights the importance of understanding the molecular control of villous trophoblast 270 
turnover as a key for improving placental and maternal health in PE. Future directions should 271 
investigate the detailed workings of how GCM1 acts to repress FLT1 and sFLT1 in the placenta.  272 
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Tissue collection 293 
First trimester (10–12 weeks of gestation) placental tissues (n = 4) were obtained with written 294 
informed consent from healthy pregnant women undergoing elective termination of pregnancy. 295 
   
 
   
 
The Institutional Review Board (IRB) of Wayne State University approved all consent forms and 296 
protocols used in this study, which abide by the NIH research guidelines. Term placental samples 297 
were obtained either by the Research Centre for Women's and Infants’ Health (RCWIH) BioBank 298 
program of Mount Sinai Hospital in Toronto, Canada, in accordance with the policies of the Mount 299 
Sinai Hospital Research Ethics Board or Women’s Health Center at Spectrum Hospital in Grand 300 
Rapids, MI. All placentas collected were approved by the IRB waiver of parental consent.  301 
Specimens were collected from age-matched idiopathic preterm without histological evidence of 302 
chorioamnionitis not complicated by PE (PTC) (n = 14; gestational age = 31-39 weeks), and 303 
pregnancies complicated by severe PE (n = 14; gestational age = 31-37 weeks) and were delivered 304 
either by Cesarean section or vaginal birth. Inclusion criteria for severe PE was in accordance with 305 
current guidelines including blood pressure > 160/110 mm Hg on two occasions longer than 6 hr 306 
apart, evidence of end-organ damage including proteinuria, with or without fetal growth restriction 307 
[54]. 308 
Explant culture 309 
For term tissues, a standardized random sampling protocol was applied dissecting random four 310 
1cm3 cuboidal sections to avoid sampling bias. The collected tissues were washed and transported 311 
to the laboratory in ice cold HBSS (Hank's Balanced Salt Solution) and processed within a 312 
maximum of 2 hr after delivery. On arrival, tissues were rinsed in chilled HBSS to remove residual 313 
blood and further dissected under a stereomicroscope to remove placental membranes and generate 314 
20-30mg pieces of villous tissues for culture. First trimester explants were cultured according to 315 
our previously published floating villous explant protocol [55].  Individual clusters of villous trees 316 
were dissected under a stereomicroscope. Post dissection, the explants were cultured overnight in 317 
500 uL of Dulbecco's modified Eagle's medium/Ham's F‐12 nutrient mixture (DMEM/F‐12; 1:1; 318 
   
 
   
 
Life Technologies; Grand Island, NY) containing 10% fetal bovine serum (FBS; Life 319 
Technologies) and 1% Gibco™ antibiotic‐antimycotic. Term explants were maintained overnight 320 
at 8% O2 with 5% CO2 at 37°C [56]. After an overnight culture, the tissues were treated with 321 
10µM Rosiglitazone (Selleckchem) or 1µM T0070907 (R&D Systems) dissolved in dimethyl 322 
sulfoxide (DMSO, Sigma Life Sciences) for 18-24 hours. DMSO alone was used as a vehicle 323 
control. Comparison of DMSO to NT (not treated placental tissues) was performed to ensure there 324 
was not an effect from DMSO. After the culture period for each treatment, replicates were snap 325 
frozen for protein and RNA extraction and stored at -80°C. The media was also collected, snap 326 
frozen and stored at -80°C. In a few samples, an extra replicate was immediately fixed in 4% 327 
paraformaldehyde for immunohistochemistry. This was included in this study as a qualitative 328 
assessment to complement RNA/Protein expression findings.  329 
Protein extraction and immunoblotting  330 
Protein extraction from tissues (20–30 mg) was performed as previously described [57]. Protein 331 
concentration was determined with BCA™ protein assay reagent (Thermo Fisher Scientific, 332 
Rockford, IL) according to the manufacturer's instructions. Equal protein amounts (35 μg) were 333 
denatured (8 min, 95°C) in Laemmli sample buffer (Bio‐Rad Laboratories; Hercules, CA) and 334 
separated using sodium dodecyl sulfate‐polyacrylamide gel electrophoresis, with subsequent semi‐335 
dry transfer (Trans‐Blot®; Bio‐Rad Laboratories) to a polyvinylidene difluoride membrane. The 336 
membranes were blocked with 5% nonfat dry milk in 1× Tris‐buffered saline containing 0.05% 337 
Tween‐20 and were incubated overnight at 4°C with anti‐GCM1 (1:5,000; Aviva, San Diego, CA), 338 
anti‐FLT1 (1:1000, Abcam), and anti‐PPARγ (1:1,000; Cell Signaling Technology) primary 339 
antibodies. Subsequently, membranes were incubated with horseradish peroxidase‐conjugated 340 
secondary antibodies for 1 hr at room temperature and were developed with Western Lightning® 341 
   
 
   
 
ECL Pro (PerkinElmer, Waltham, MA). Signals were visualized using a ChemiDoc™ Imaging 342 
System (Bio‐Rad Laboratories) and Image Lab Version 5.1 software (Bio‐Rad Laboratories). 343 
Densities of immunoreactive bands were measured as arbitrary units by the ImageJ software (NIH, 344 
Bethesda, MD). Protein levels were normalized to a housekeeping protein β‐actin (1:4,000; 345 
Abcam). Protein expression values are reported as relative to β‐actin.  346 
ELISA 347 
The media collected from PE, PTC, and first trimester placental explant cultures was assayed for 348 
levels of sFLT1 using the Human VEGFR1/Flt-1 DuoSet kit (R&D Systems, Minneapolis, MN) 349 
according to the manufacturer’s instruction. Culture media was centrifuged at 4,500 x g for 10 350 
minutes at 4°C to pellet all cell/tissue debris and the supernatant was used for ELISA analysis. The 351 
optical density of the final-colored reaction product was measured at 450 nm using a SoftMax Pro5 352 
or a multispectral UV/VIS (Bio-Tek, VT) plate reader. A standard curve was used to calculate 353 
protein content, and this was normalized over wet weight of the explant to obtain the amount of 354 
protein secreted per milligram of explant tissue.  355 
RNA extraction and qPCR analysis 356 
The tissue was lysed in Qiazol and RNA was extracted using RNeasy Plus Universal Mini kit 357 
(Qiagen, Germany) as per the manufacturer’s protocol.  The extracted RNA was quantified using 358 
Nanodrop and 1µg was reverse transcribed using iScript RT synthesis kit (Bio-Rad Laboratories, 359 
CA).  Real-time PCR was performed on the Bio-Rad CFX384 real time system in triplicates in 360 
10uL total reaction volume containing 10 ng of template cDNA, 5µL of SYBR-green master mix 361 
(LuminoCT, Sigma-Aldrich, MO) and 500nM of primers. The primers used for assessing the 362 
   
 
   
 
expression levels of target and housekeeping genes are outlined in Table 1.  Data was analyzed 363 
using the delta-delta CT method as described in [58]. 364 
PPARγ Transcription Factor Assay 365 
Nuclear proteins were isolated from first trimester tissue after treatment with Rosiglitazone 366 
(10μM), T0070907 (1nM) and DMSO using a Nuclear Extract Kit (ActiveMotif, Carlsbad, 367 
California). The assay was performed using PPARγ binding assay (TransAM, ActiveMotif, 368 
Carlsbad, California) following the manufacturer’s protocol. Briefly, 3μg of nuclear proteins from 369 
treatment and control groups were used. The proteins from each group were added to the provided 370 
96 well plate (in triplicates) and volumes were adjusted to 10uL using the complete lysis buffer 371 
from the kit. 5ug of given positive control and complete binding buffer containing 40pmol of the 372 
consensus site (from the kit) was then added to each well. The plate was incubated for 1 hour 373 
followed by 3 washes with the 200uL of 1X wash buffer. 100uL of the supplied PPARγ antibody 374 
was then added to all wells and the plate was incubated again for 1 hour at RT. After the incubation, 375 
the wells were washed again 4 times and 100uL of developing solution was then added to each 376 
well and incubated for 5 mins. The reaction was stopped using 100uL of Stop solution and the 377 
absorbance was read at 665nm. The absorbance for the blank wells was subtracted from all the 378 
readings and then values from Rosiglitazone and T0070907 samples were normalized to the values 379 
from DMSO vehicle for comparison between the treatments.  380 
Immunohistochemistry 381 
Immunostainings of placental villi were performed as described in [59].  Briefly, the sections were 382 
deparaffinized and rehydrated, followed by antigen retrieval using Dako Target retrieval solution 383 
(Agilent-DAKO, USA).  The intrinsic peroxidase activity was then quenched by incubating the 384 
   
 
   
 
sections with 3% Hydrogen peroxide (Fisher Scientific, MA) for 30 mins at RT, followed by a 385 
wash with 1X PBS.  The sections were then incubated overnight at 4°C with anti-FLT1 (Santa 386 
Cruz, TX) or 10μg/ml nonimmune Rabbit IgG (Jackson Immunoresearch, PA) (used as a negative 387 
control).  The following day, the slides were washed 3 times (5 minutes/wash) with 1X PBS 388 
containing 0.1% Tween 20. The samples were then incubated for 30 min with a peroxidase-389 
conjugated polymer coupled to anti-rabbit IgG (EnVision Systems Peroxidase, Agilent-DAKO, 390 
USA).  The peroxidase was visualized with 3,3-diaminobenzidine (DAB, Agilent-DAKO, USA) 391 
and hydrogen peroxide for 5 min.  Tissues were counterstained with hematoxylin, dehydrated and 392 
were cover slipped.  The staining was visualized using Nikon Eclipse 90i epifluorescence 393 
microscope (Nikon Inc., Japan) and the images were analyzed using ImageJ software.  394 
siRNA-mediated GCM1 suppression 395 
For silencing, Silencer™ Select Pre-Designed siRNA assays (Thermo Fischer) were used.   For 396 
GCM1 specific knockdown, assay ID s16199 was used and a Cy™3-labeled scramble sequence 397 
was used a negative control (AM4621, ThermoFisher). A non-silencing control was additionally 398 
incorporated as a technical control to exclude any effects of the electroporation procedure used for 399 
silencing. The tissues were electroporated using the P3 Primary Cell 4D-NucleofectorTM X Kit L 400 
and the NucleofactorTM 2b device (Lonza, Switzerland) following the manufacturer’s kit protocol. 401 
First trimester villous explants were cultured overnight in Dulbecco's modified Eagle's 402 
medium/Ham's F‐12 nutrient mixture (DMEM/F‐12; 1:1; Life Technologies; Grand Island, NY) 403 
containing 10% fetal bovine serum (FBS; Life Technologies) and 1% Gibco™ antibiotic‐404 
antimycotic at 8% O2. On day 2, the explants were placed in the cuvette (2 explants/cuvette) along 405 
with 100uL of electroporation solution (10uL of silencing probe mix + 90uL of electroporation 406 
buffer). The program U017 was used for electroporation after which the explants were taken out 407 
   
 
   
 
and cultured in fresh media for 48 hours. After the culture period, one set of explants were 408 
processed for immunohistochemistry by fixing in 4% paraformaldehyde and another set was 409 
frozen in 700uL of Qiazol to be used for RNA expression studies. The media was collected and 410 
frozen to be used later for sFLT1 analysis using ELISA. 411 
Statistical Analysis  412 
All statistical analysis was performed with GraphPad Prism 7.0 software. Raw mRNA and protein 413 
expressions were normalized to respective housekeeping genes or protein. ELISA data was 414 
normalized based on semi dry-tissue weight. Relative expression/secretion values from untreated 415 
tissues (Figure 1) were analyzed by student’s t-test after determination if samples are normally 416 
distributed and an F-test was applied to determine variances between groups which was then used 417 
in the parameters for the t-test. Raw mRNA and protein expression values from tissues treated 418 
with either DMSO, Rosiglitazone and T0070907, or GCM1-siRNA and scramble siRNA (Figures 419 
2-4) were normalized to respective housekeeping genes or protein. Relative expression or secretion 420 
values for each tissue sets were subsequently normalized to respective DMSO (vehicle control, set 421 
equal to 1) or scramble siRNA control (set equal to 1) represented by a dotted line on the graphs. 422 
Groups were then analyzed by student’s t-test, after determination if samples are normally 423 
distributed and an F-test was applied to determine variances between groups which was then used 424 
in the parameters for the t-test.  p<0.05 is considered significant and is indicated with (*) on each 425 
graph. Data is reported as Mean±S.E.M [60]. All sample numbers are reported as per group, for 426 
example, n=6 designates 6 samples per treatment/group.  427 
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Novelty and Significance 576 
What Is New? 577 
• Strong FLT1 production occurs in dysregulated areas of syncytiotrophoblast, accompanied 578 
by low expression of PPARγ and GCM1 which regulate villous trophoblast syncytialization 579 
in the preeclamptic placenta.  580 
• Silencing of GCM1 in the first trimester placenta leads to an induction of sFLT1.  581 
• We are the first to show that induction of PPARγ increases GCM1 and reduces sFLT1 582 
expression in the placenta. 583 
What Is Relevant? 584 
• Restoring the PPARγ-GCM1 syncytialization axis provides a physiological ‘break’ on sFLT1 585 
production from severely preeclamptic placenta.   586 
Summary 587 
Aberrant villous trophoblast turnover contributes to pathologic levels of sFLT1 and this can be 588 
halted by restoration of the PPARγ-GCM1 syncytialization axis in the preeclamptic placenta.  589 
Tables 590 
Table 1. qPCR Primer Sequences 591 
Gene Name Gene Symbol Sequence 
Cytochrome - C 1 Cyc1 5'-CAT CAT CAA CAT CTT GAG CC-3' 
   
 




Figure 1. Placentas from women with sPE exhibit higher sFLT1 secretion and FLT1 594 
expression accompanied with lower expressions of PPARγ and GCM1. sFLT1 secretion was 595 
significantly higher secreted by sPE compared to gestational-age matched control (PTC) 596 
(2361.3±198pg vs. 3326.8±178.8pg, n=5, p=0.0067) (A). This finding corresponds with higher 597 
expression of FLT1 protein in sPE compared to control (n=6, p=0.0167) (B). Immunostaining for 598 
total-FLT1 (FLT1 and sFLT1 variants) shows light staining in the syncytiotrophoblast of PTC 599 
tissues compared to a more intense signal in sPE placenta (E). Immunoblotting assessment 600 
revealed sPE placentas exhibit lower protein expression of PPARγ (n=6, p=0.0042) and GCM1 601 
(n=14, p=0.0001) compared to PTC (C, D). Representative western blots are shown in (F). 602 
(Relative mRNA and protein expression were determine by normalization to housekeeping genes 603 
or protein, followed by a student’s t-test to determine significant differences between groups, * 604 
p<0.05, ** p<0.01, Rosi=Rosiglitazone, T007=T0070907, bar plots and data reported are 605 
5'-CAG ATA GCC AAG GAT GTG TG-3' 
Tyrosine 3-monooxygenase Ywhah 
5'- CCG CCA GGA CAA ACC AGT AT -3' 
5'- ACT TTT GGT ACA TTG TGG CTT CAA -3' 
TATA Box Binding Protein Tbp 
5'-CAC ATC ACA GCT CCC CAC CA-3' 
5'-TGC ACA GGA GCC AAG AGT GAA-3' 
Glial cell missing 1 Gcm1 
5'-TGA ACA CAG CAC CTT CCT C-3' 
5'-CCA CTG TAA CTA CCA GGC AAT-3' 
Soluble fms-like tyrosine kinase 1 sFlt1 
5‘- CCT CAA ATG ATC CAC CTG CCT-3‘ 
5‘- CAG GAA GCA CCA TAC CTC CTG -3‘ 
   
 
   
 
presented mean ± SEM, PE = preeclampsia, PTC = preterm healthy control, SN = Syncytial 606 
Knots, scale bar = 50 μm, bar plots are presented as mean ± SEM.).       607 
 608 
Figure 2. Rosiglitazone increases PPARγ activity and GCM1 mRNA expression while 609 
reducing sFLT1 secretion in the first trimester placenta. Treatment with Rosiglitazone caused 610 
a significant increase in PPARγ activity (p<0.05, n=3) (A). T0070907 did not cause a significant 611 
change in PPARγ activity (A). Rosiglitazone significantly upregulated PPARγ (p=0.0446, n=4) 612 
and GCM1 (p=0.0402, n=4) protein expression (B, C, F). T0070907 did not cause a significant 613 
change in PPARγ or GCM1 protein expression (B, C, F). Rosiglitazone significantly upregulated 614 
GCM1 mRNA expression (p=0.0433, n=4) (D). T0070907 significantly reduced GCM1 mRNA 615 
   
 
   
 
expression (p=0.02, n=4) (D). Rosiglitazone also caused a significant  reduction in sFLT1 616 
secretion (p=0.025, n=3) (E). Antagonizing PPARγ by T0070907 did not cause a statistically 617 
significant change in sFLT1 secretion (E). (Relative mRNA and protein expression were determine 618 
by normalization to housekeeping genes or protein. Relative expression values for individual tissue 619 
sets were normalized to DMSO (vehicle control, dotted line, set equal to 1) and subsequent 620 
statistical analysis was performed by student’s t-test to determine significant differences between 621 
groups,* p<0.05, ns=p>0.05, NT=not treated, Rosi=Rosiglitazone, T007=T0070907, bar plots 622 
and data reported are reported as mean ± SEM).  623 
   
 
   
 
 624 
Figure 3. GCM1 reduction increases total-FLT1 expression and sFLT1 secretion in first 625 
trimester explants. In our first trimester explant model, siRNA-mediated silencing of GCM1 626 
caused a significant reduction of GCM1 mRNA expression (p=0.031, n=3) (A). Similarly, western 627 
blot shows GCM1 protein expression appeared to be decreased in the GCM1-silenced tissues in 628 
comparison to the scramble siRNA and no-treatment controls (C). sFLT1 secretion was 629 
significantly increased in the GCM1-silenced explants (p=0.0389, n=3) (B). Similarly, placental 630 
expression of total-FLT1 protein (FLT1 and sFLT1 variants) was induced in the 631 
   
 
   
 
syncytiotrophoblast of the first trimester explants, after GCM1 knockdown (D). (Relative mRNA 632 
expression was normalized to housekeeping genes. sFLT1 secretion (pg/mL) data were normalized 633 
based on tissue weight. Relative expression/secretion values for individual tissue sets were 634 
normalized to the scramble siRNA control (dotted line, set equal to 1) and subsequent statistical 635 
analysis was performed by student’s t-test was performed to determine significant differences 636 
between groups, NT=not treated, * p<0.05, ns= p>0.05, bar plots are reported as mean ± SEM). 637 
 638 
Figure 4. Rosiglitazone increases expression of PPARγ and GCM1 while simultaneously 639 
decreasing sFLT1 in sPE placenta. PPARγ protein expression significantly increased in sPE 640 
placenta after Rosiglitazone treatment (p=0.0051, n=4) (A/B). GCM1 mRNA significantly 641 
increased in the sPE placenta by Rosiglitazone treatment (p=0.0162, n=9). GCM1 mRNA 642 
   
 
   
 
expression significantly reduced in the sPE placenta after treatment with T0070907 (p=0.001, n=9) 643 
(C). sFLT1 mRNA was significantly reduced in the sPE placenta after Rosiglitazone treatment. 644 
No significant change in sFLT1 mRNA expression was observed after exposure to T0070907 (B).  645 
(Relative mRNA/protein expressions were determined by normalization to respective 646 
housekeeping genes/protein. Relative expression values for individual tissue sets were normalized 647 
to DMSO (vehicle control, dotted line, set equal to 1) and subsequent statistical analysis was 648 
performed by student’s t-test to determine significant differences between groups, *p<0.05, 649 
**p<0.01, ns=p>0.05, NT= not treated, Rosi=Rosiglitazone, T007=T0070907, bar plots are 650 
reported as mean ± SEM). 651 
 652 
